Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations

Table 2

Clinical trials recently completed in DSRCT.

Clinical trial (ID); phase	Drugs	Status	Assigned intervention
NCT01154452; phase 1B/II	Vismodegib (hedgehog inhibitor) and NOTCH inhibitor RO4929097	Completed	Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients with Advanced or Metastatic Sarcoma
NCT00563680; phase II	Drug: AMG 479 (IGF-R1 Ab)	Completed	QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing’s Family Tumor and Desmoplastic Small Round Cell Tumors
NCT00062205; phase I, II	Drug: imatinib mesylate	Completed	Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round Cell Tumor
NCT00055952; phase II	Drug: exatecan mesylate (camptothecin)	Completed	Exatecan Mesylate in Treating Patients With Ewing’s Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
NCT00720174; phase I	Biological: cixutumumab (IGF-1R Ab); drug: doxorubicin hydrochloride; other: laboratory biomarker analysis	Completed	Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
NCT00436657; phase I	Drug: CHPP of cisplatin; procedure: abdominal surgery	Completed	Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer
NCT00093821; phase I	Drug: tanespimycin (HSP90 inhibitor)	Completed	Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors